MicroRNA-206 suppresses hypoxia-inducible factor-1α/PFKFB3-mediated glycolysis to inhibit recurrence and metastasis of hepatocellular carcinoma after incomplete radiofrequency ablation

Figure 2 Changes in serum biomarker levels in patients undergoing complete or incomplete radiofrequency ablation. A: Serum hypoxia-inducible factor-1α levels measured preoperatively and 1 week after radiofrequency ablation (RFA) in the complete ablation group (n = 35) and incomplete ablation group (n = 10); B: Serum microRNA-206 levels in the same patient cohorts (n = 35 vs n = 10); C: Changes in serum glucose levels before and after RFA (n = 45); D: Changes in serum pyruvate levels before and after RFA (n = 45). Data are presented as mean ± SD. Student’s t-test was used for comparisons. ^aP < 0.05; ^bP < 0.01. RFA: Radiofrequency ablation; miR-206: MicroRNA-206; HIF-1α: Hypoxia-inducible factor-1α.